Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol

Lee, Chau Hung; Vellayappan, Balamurugan; Taupitz, Matthias; Hamm, Bernd; Asbach, Patrick

doi:10.1007/s00330-019-06321-6

Cited by 3 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have compared GB to other GBCAs using contrast-enhanced MRI in the context of brain-lesion imaging [19][20][21][22] and prostatic nodules, 23 with some showing similar image quality determinations 19,20 and others showing superior image quality associated with GB. 21,23 However, results from morphological image quality studies are not readily transferable to MRA because GBCAs agents interact with blood differently than tissue. 24 Other studies have drawn GBCA comparisons in vascular territories other than the SAV.…”

Section: Discussionmentioning

confidence: 99%

MRA of the Supraaortic Vasculature: Comparison of Gadobutrol and Gadoterate Meglumine at 1.5 T

Cerne

Pathrose

Singer

et al. 2021

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background: Gadobutrol (GB) and gadoterate meglumine (GM) are contrast agents used for contrast-enhanced magnetic resonance angiography (CEMRA). Supraaortic vasculature (SAV) CEMRAs are used to evaluate stroke risk and neurologic symptoms. There is a need to compare the SAV CEMRA image quality obtained with GB and GM. Purpose: To intra-individually compare MRA images obtained with equimolar GB and GM at 1.5 T in the SAV. Study Type: Prospective, crossover. Population: Twenty-eight subjects (54 AE 13 years; 17 female). Field Strength/Sequence: 1.5 T; three-dimensional (3D) gradient recalled echo. Assessment: Quantitative image quality was measured by normalized signal intensity (SI n ) [SI n = SI blood/SD blood] and contrast ratio (CR) [CR = SI blood/SI muscle], determined by an observer (JWC) with 1 year of vascular imaging experience. Three radiologists (AS, PA, and MU) with (5, 5, and 6 years of) vascular imaging experience evaluated image quality by Likert-scale ratings (of image impression, wall conspicuity, and artifact absence). Statistical Tests: SI n and CR were compared with paired t-tests or Wilcoxon signed-rank tests and Bland-Altman plots. Qualitative ratings were compared with Wilcoxon signed-rank test. Results: No significant difference in SI n was found between GB and GM. CRs with GB were significantly higher than GM at the right common carotid (6.9 AE 2.5 vs. 4.8 AE 1), left internal carotid (7.3 AE 2 vs. 4.4 AE 1.2), right internal carotid (7.7 AE 2.2 vs. 5 AE 1.1), and left vertebral (6.6 AE 2.2 vs. 4.5 AE 1.1) arteries. Bland-Altman plots showed relatively greater differences between GB and GM at higher CRs and SI n s. GM showed significantly higher artifact than GB (3.56 AE 0.52 vs. 3.36 AE 0.46) and significantly lower overall image quality (10.73 AE 1.45 vs. 11.26 AE 1.58) at the left vertebral artery. Data Conclusion: At 1.5 T and equimolar demonstration, GB (0.1 mL/kg, i.e., 0.1 mmol/kg) showed higher CRs in the SAV compared to GM (0.2 mL/kg, i.e., 0.1 mmol/kg) at most vessels. Subjective image quality was not significantly different between the two agents for most vessels. Level of Evidence: 2 Technical Efficacy: Stage 2

show abstract

Section: Discussionmentioning

confidence: 99%

MRA of the Supraaortic Vasculature: Comparison of Gadobutrol and Gadoterate Meglumine at 1.5 T

Cerne

Pathrose

Singer

et al. 2021

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Previous studies have compared the performance of gadobutrol and gadoterate meglumine for CE-MRA demonstrating variable results at other body regions (13)(14)(15)(16)(17)(18)(19)(20). Wuesten et al found that, for low-dose, high temporal resolution CE-MRA of carotid artery aneurysms at 3T, gadobutrol was superior to gadoterate meglumine in terms of contrast-to-noise ratios (CNR) and depiction of morphological details (13) Due to their paramagnetic nature, GBCAs shorten the tissue relaxation time, resulting in increased tissue signal intensity on T1-weighted images (23).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, gadobutrol is administered at half the volume of gadoterate meglumine, even while they have the same amount of gadolinium, due to differences in formulation (gadobutrol is formulated at a concentration of 1 mmol/mL while gadoterate meglumine at 0.5 mmol/mL). Despite these differences in relaxivity and in formulated drug concentration, previous studies on CE-MRA for various vascular regions have failed to conclusively demonstrate differences in diagnostic performance of one agent over the other (13)(14)(15)(16)(17)(18)(19)(20). Therefore, the purpose of this study was to systematically compare the intra-individual qualitative image quality as well as quantitative aortic dimensions and signal parameters between equal doses of gadobutrol and gadoterate meglumine for static 3D CE-MRA in patients with thoracic aortic disease.…”

Section: Introductionmentioning

confidence: 99%

“…Haneder et al found that, equimolar doses, gadobutrol yielded signi cantly higher SNR and CNR while gadoterate was better rated in terms of overall image quality and diagnostic con dence for the evaluation of peripheral arterial occlusive disease (18). Hoelter et al found that, gadobutrol resulted in a signi cantly higher SNR/CNR and better delineation of the intracranial vasculature when compared to gadoterate meglumine for cervical and cerebral CE-MRA at 1.5T(19).Lee et al found that, at equimolar doses, increased gadolinium delivery over time using gadobutrol provides higher relative enhancement parameters in benign prostatic hyperplasia nodules compared with gadoterate meglumine but does not translate into improved SNR or CNR(20). However, results from CE-MRA studies of certain anatomical areas are not transferable to other areas without careful interrogation because the injection volume, injection rate, and the contrast agent travel time in uence the concentration of GBCA in the region of interest signi cantly.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Performance of Gadobutrol and Gadoterate Meglumine for Contrast-Enhanced Magnetic Resonance Angiography of the thoracic aorta at 1.5T

Pathrose¹,

Singer²,

Cerne³

et al. 2022

Preprint

View full text Add to dashboard Cite

PURPOSE The purpose of this study was to systematically compare the intra-individual image quality, signal parameters, and aortic dimensions between equal doses of gadobutrol (GB) and gadoterate meglumine (GM) in patients undergoing contrast-enhanced MRA of the thoracic aorta. METHODS 33 patients (50 ± 12 years, 30M) with aortic disease who underwent GB-enhanced thoracic aortic MRA were prospectively recruited to undergo a GM-enhanced MRA within 8 weeks. MRAs were obtained after administration of 0.2mL/kg of 1.0M GB and 0.4mL/kg of 0.5M GM at flow rate of 2mL/s. Aortic luminal signal intensities (SI) and contrast ratios (CR) with respect to trapezius were measured at three regions. Aortic orthogonal diameters were measured at six regions. Overall image quality, vessel wall conspicuity, and artifacts were scored by two radiologists. RESULTS GB demonstrated significantly higher SI at all regions when compared to GM (AAo: 234 ± 97 vs. 116 ± 29, p < 0.001; Arch: 206 ± 92 vs. 99 ± 24, p < 0.001; DAo: 265 ± 132 vs. 102 ± 28, p < 0.001). CR at all regions (AAo: 3.0 ± 1.1 vs. 2.7 ± 1.0, p = 0.503; Arch: 2.7 ± 1.0 vs. 2.8 ± 1.1, p = 0.599; DAo: 3.3 ± 1.5 vs. 3.0 ± 1.1, p = 0.099) and aortic diameters at all regions did not show any significant difference between GB and GM. Overall image quality, vessel wall conspicuity, and artifact scores did not significantly differ between GB and GM. CONCLUSION This intra-individual study found that for contrast-enhanced MRA of the thoracic aorta, CR, aortic diameter measurements, overall image quality, vessel wall conspicuity, and artifact scores were comparable between equal doses of GB and GM. However, GB showed significantly higher aortic luminal SI when compared to GM.

show abstract

“…This method takes into account which contrast media is used. Studies have shown that there is a difference in relative enhancement depending on the used contrast media, even when equimolar doses are applied at the same injection rate, but it does not influence pharmacokinetic parameters [18].…”

Section: Introductionmentioning

confidence: 99%

Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate—Can We Make Better Use of It?

Silva¹,

Benšić

Dupan

et al. 2022

Tomography

View full text Add to dashboard Cite

We sought to investigate whether quantitative parameters from a dynamic contrast-enhanced study can be used to differentiate cancer from normal tissue and to determine a cut-off value of specific parameters that can predict malignancy more accurately, compared to the obturator internus muscle as a reference tissue. This retrospective study included 56 patients with biopsy proven prostate cancer (PCa) after multiparametric magnetic resonance imaging (mpMRI), with a total of 70 lesions; 39 were located in the peripheral zone, and 31 in the transition zone. The quantitative parameters for all patients were calculated in the detected lesion, morphologically normal prostate tissue and the obturator internus muscle. Increase in the Ktrans value was determined in lesion-to-muscle ratio by 3.974368, which is a cut-off value to differentiate between prostate cancer and normal prostate tissue, with specificity of 72.86% and sensitivity of 91.43%. We introduced a model to detect prostate cancer that combines Ktrans lesion-to-muscle ratio value and iAUC lesion-to-muscle ratio value, which is of higher accuracy compared to individual variables. Based on this model, we identified the optimal cut-off value with 100% sensitivity and 64.28% specificity. The use of quantitative DCE pharmacokinetic parameters compared to the obturator internus muscle as reference tissue leads to higher diagnostic accuracy for prostate cancer detection.

show abstract

Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol

Cited by 3 publications

References 42 publications

MRA of the Supraaortic Vasculature: Comparison of Gadobutrol and Gadoterate Meglumine at 1.5 T

MRA of the Supraaortic Vasculature: Comparison of Gadobutrol and Gadoterate Meglumine at 1.5 T

Evaluating the Performance of Gadobutrol and Gadoterate Meglumine for Contrast-Enhanced Magnetic Resonance Angiography of the thoracic aorta at 1.5T

Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate—Can We Make Better Use of It?

Contact Info

Product

Resources

About